Rheumatoid Arthritis Clinical Trial
Official title:
Antimalarial and Covid 19 in Rheumatoid Arthritis
The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment
of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement
of clinical and laboratory parameters, but their slow onset of action differ them from
glucocorticoids and nonsteroidal antiinflammatory agents.
Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin
manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately
active rheumatoid arthritis (RA).
The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment
of rheumatoid arthritis and systemic lupus erythematosus.(1) . These compounds lead to
improvement of clinical and laboratory parameters, but their slow onset of action differ them
from glucocorticoids and nonsteroidal antiinflammatory agents.
Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin
manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately
active rheumatoid arthritis (RA).
It is difficult to carefully evaluate the onslaught of information that has emerged regarding
potential COVID-19 therapies within a few months' time in early 2020. A brief but detailed
approach regarding how to evaluate resulting evidence of a study has been presented by F.
Perry Wilson, MD, MSCE. By using the example of a case series of patients given
hydroxychloroquine plus azithromycin, he provides clinicians with a quick review of critical
analyses.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
| Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
| Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
| Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
| Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
| Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
| Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
| Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
| Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
| Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
| Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
| Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
| Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
| Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |